©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2020; 11(6): 348-369
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.348
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.348
Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review
Joanna Szczepanek, Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Toruń 87100, Poland
Author contributions: Szczepanek J conducted an analysis of literature data and wrote and revised the paper.
Conflict-of-interest statement: The author declares that there are no conflicts of interest.
Corresponding author: Joanna Szczepanek, PhD, Associate Research Scientist, Centre for Modern Interdisciplinary Technology, Nicholas Copernicus University, Wileńska 4, Toruń 87100, Poland. szczepanekj@umk.pl
Received: January 31, 2020
Peer-review started: January 31, 2020
First decision: April 18, 2020
Revised: May 18, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: June 24, 2020
Processing time: 145 Days and 0 Hours
Peer-review started: January 31, 2020
First decision: April 18, 2020
Revised: May 18, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: June 24, 2020
Processing time: 145 Days and 0 Hours
Core Tip
Core tip: MicroRNAs (miRNAs) are small endogenous gene expression regulators. By performing the function of oncogenes and/or tumor suppressors, they have become interesting candidates for early diagnosis, accurate classification, and predictors of prognosis in the most common childhood cancers, i.e. acute leukemia. The possibility of using modulation of miRNA levels in targeted therapy is also important. Because they are noninvasive and relatively easy to determine in biological samples, miRNAs are gaining increasing attention from scientists and clinicians.